Skip to main content

Advertisement

SpringerLink
Log in

TNFα blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

High cost deters continuous use of tumor necrosis factor α blockers (TNFi) in developing countries. The objective of this study was to evaluate outcome and expenditure incurred in Spondyloarthritis (SpA) patients beyond a year of follow-up after receiving four doses of infliximab (IFX) over and above background therapy of methotrexate (MTX) and sulfasalazine (SSZ) combination. Electronic medical records were screened for patients with SpA satisfying the Assessment of Spondyloarthritis International Society (ASAS) criteria between 2008 and 2014. Patients who completed at least 1 year of follow-up after receiving four doses of IFX (5 mg/kg at 0, 2, 6, and 14 weeks) on a background therapy of MTX (10–25 mg/week) and SSZ (2–3 g/day) combination were enrolled after obtaining an informed consent. Primary outcome assessed was “time to disease flare”. Changes in acute phase reactants, patient reported outcomes (BASDAI, BASFI), and cost were also assessed. Forty-five patients were enrolled. Mean (SD) duration of follow up after fourth IFX dose was 28.9 (18.7) months. Disease flare occurred in 33.3% (15/45) after a mean (SD) duration of 14.5 (10.8) months as compared to 4–6 months described in literature on discontinuing TNFi. Reduction in ESR, CRP, BASDAI and BASFI continued to be statistically significant at follow-up as compared to baseline. As compared to continuous IFX therapy, this treatment reduced cost by 57.1% for each patient-month of follow-up. Short course IFX dosing followed by continuation of MTX and SSZ combination can prolong time to disease flare and decrease requirement for additional IFX dose in SpA. This regimen could be a cost saving option for patients with SpA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sieper J, Rudwaleit M, Khan MA, Braun J (2006 Jun) Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 20(3):401–417

    Article  PubMed  Google Scholar 

  2. Zeidler H, Amor B (2011 Jan) The assessment in spondyloarthritis international society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. Ann Rheum Dis 70(1):1–3

    Article  PubMed  Google Scholar 

  3. Baraliakos X, Berg R van den Braun J, van der Heijde D (2012) Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology kes026

  4. Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MMS, Tanjong Ghogomu E et al (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD005468

    Google Scholar 

  5. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester G-R et al (2011 Sep) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatol Oxf Engl. 50(9):1690–1699

    Article  CAS  Google Scholar 

  6. P Keith M. Overview of Drug Therapy for Spondyloarthritis. Rheumatol Curr Res [Internet]. 2013 [cited 2016 Aug 31];3(2). Available from: http://www.omicsonline.org/overview-of-drug-therapy-for-spondyloarthritis-2161-1149.1000119.php?aid=18720

  7. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM (2000) Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 19(2):114–117

    Article  CAS  PubMed  Google Scholar 

  8. Creemers MC, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL (1995 Jun) Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 22(6):1104–1107

    CAS  PubMed  Google Scholar 

  9. Lale Altan MY (2001 Jan 1) Ümit Bingöl, YÜksel Karakoç, Saadet Aydıner, Mustafa Yurtkuran. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 30(5):255–259

    Article  Google Scholar 

  10. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM (2000) Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 29(3):160–162

    Article  CAS  PubMed  Google Scholar 

  11. Chen J, Veras MMS, Liu C, Lin J (2013) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2:CD004524

    Google Scholar 

  12. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Muñoz-Valle JF, Gamez-Nava JI (2004) Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 31(8):1568–1574

    CAS  PubMed  Google Scholar 

  13. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K et al (2006 Sep) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147–1153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Clegg DO, Reda DJ, Abdellatif M (1999 Nov) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42(11):2325–2329

    Article  CAS  PubMed  Google Scholar 

  15. Ferraz MB, Tugwell P, Goldsmith CH, Atra E (1990 Nov) Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 17(11):1482–1486

    CAS  PubMed  Google Scholar 

  16. Dougados M, Boumier P, Amor B (1986 Oct 11) Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J Clin Res Ed 293(6552):911–914

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E et al (2011 Jun 1) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896–904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Chen J, Lin S, Liu C (2014) Sulfasalazine for ankylosing spondylitis. In: Cochrane Database of Systematic Reviews [Internet]. John Wiley & Sons, Ltd; [cited 2016 Aug 31]. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004800.pub3/abstract

  19. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS et al (2011 Jun 1) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63(6):1543–1551

    Article  CAS  PubMed  Google Scholar 

  20. Sandhya P, Danda D, Mathew J, Gattani A (2011 Jul) Outcome of patients with seronegative spondyloarthritis continuing sulphasalazine and methotrexate after a short course of infliximab therapy—experience from a tertiary care teaching hospital in South India. Clin Rheumatol 30(7):997–1001

    Article  CAS  PubMed  Google Scholar 

  21. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT et al (2011 Jan) The assessment of Spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31

    Article  CAS  PubMed  Google Scholar 

  22. CDC | TB | Treatment | Treatment Regimens for Latent TB Infection (LTBI) [Internet]. [cited 2017 May 30]. Available from: https://www.cdc.gov/tb/topic/treatment/ltbi.htm

  23. Callhoff J, Sieper J, Weiß A, Zink A, Listing J (2015 Jun) Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 74(6):1241–1248

    Article  CAS  PubMed  Google Scholar 

  24. Ai J-W, Ruan Q-L, Liu Q-H, Zhang W-H (2016, e10) Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect 5

  25. Sharma SK, Mohanan S, Sharma A (2012) Relevance of latent TBinfection in areas of high TB prevalence. Chest 142(3):761–773

    Article  PubMed  Google Scholar 

  26. WHO | Guidelines on the management of latent tuberculosis infection [Internet]. WHO. [cited 2017 Jan 7]. Available from: http://www.who.int/tb/publications/latent-tuberculosis-infection/en/

  27. Organisation mondiale de la santé (2015) Global Tuberculose Report: 2015. Word Health Organization, Genève (Suisse)

    Google Scholar 

  28. Jois RN, Leeder J, Gibb A, Gaffney K, Macgregor A, Somerville M et al (2006 Dec 1) Low-dose infliximab treatment for ankylosing spondylitis—clinically- and cost-effective. Rheumatology 45(12):1566–1569

    Article  CAS  PubMed  Google Scholar 

  29. Sidiropoulos P, Kritikos HD, Siakka P, Mamoulaki M, Kouroumali H, Voudouris K et al (2005) Low-dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol 23(4):513

    CAS  PubMed  Google Scholar 

  30. Keeling S, Oswald A, Russell AS, Maksymowych WP (2006 Mar) Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. J Rheumatol 33(3):558–561

    CAS  PubMed  Google Scholar 

  31. Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE et al (2016) Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. RMD Open 2(2):e000272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Breban M, Ravaud P, Claudepierre P, Baron G, Henry Y-D, Hudry C et al (2008 Jan 1) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58(1):88–97

    Article  CAS  PubMed  Google Scholar 

  33. Gossec L (2006) Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Rheumatology 45(7):859–862

    Article  CAS  PubMed  Google Scholar 

  34. Sengupta S, Ray J, Ghosh B (2015) Quality of life and clinical response to on-demand maintenance doses of infliximab in patients with ankylosing spondylitis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 21(7):355–358

    Google Scholar 

  35. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–R444

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Balsa A, Martín-Mola E, Seoane-Mato D et al (2016) Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatol Oxf Engl. 55(7):1188–1194

    Article  Google Scholar 

  37. Lie E, Kristensen LE, Forsblad-d’Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT et al (2015) The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 74(6):970–978

    Article  CAS  PubMed  Google Scholar 

  38. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EMA et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69(6):976–986

    Article  CAS  PubMed  Google Scholar 

  39. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73(1):132–137

    Article  CAS  PubMed  Google Scholar 

  40. Nissen MJ, Ciurea A, Bernhard J, Tamborrini G, Mueller R, Weiss B et al (2016) The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti–tumor necrosis factor therapy in patients with axial spondyloarthritis. Arthritis Rheumatol 68(9):2141–2150

    Article  CAS  PubMed  Google Scholar 

  41. Reveille JD, Ximenes A, Ward MM (2012) Economic considerations of the treatment of ankylosing spondylitis. Am J Med Sci 343(5):371–374

    Article  PubMed  PubMed Central  Google Scholar 

  42. Kumar AS, Chen LC, Choudhury M, Ganju S, Mahajan V, Sinha A et al (2011) Financing health care for all: challenges and opportunities. Lancet 377(9766):668–679

    Article  PubMed  Google Scholar 

  43. Balarajan Y, Selvaraj S, Subramanian SV (2011) Health care and equity in India. Lancet 377(9764):505–515

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Elalouf O, Elkayam O (2015) Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis. Ther Clin Risk Manag 11:1719–1726

    PubMed  PubMed Central  Google Scholar 

  45. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatol Oxf Engl 46(9):1450–1453

    Article  CAS  Google Scholar 

  46. Maas F, Spoorenberg A, Brouwer E, Bos R, Efde M, Chaudhry RN, et al. Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Blocking Therapy: A Prospective Longitudinal Observational Cohort Study. PLoS ONE [Internet]. 2015 Apr 16 [cited 2016 Dec 14];10(4). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400173/

Download references

Acknowledgements

We would like to acknowledge the Institutional Review Board for approving and providing the necessary funding for the study.

Author information

Authors and Affiliations

  1. Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, Tamil Nadu, 632004, India

    Aswin M. Nair, P. Sandhya & Debashish Danda

  2. Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India

    Bijesh Yadav

Authors
  1. Aswin M. Nair
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Sandhya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bijesh Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Debashish Danda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Debashish Danda.

Ethics declarations

Disclosures

None.

Electronic supplementary material

ESM 1

(DOCX 408 kb)

ESM 2

(DOCX 16 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nair, A.M., Sandhya, P., Yadav, B. et al. TNFα blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis. Clin Rheumatol 36, 2243–2251 (2017). https://doi.org/10.1007/s10067-017-3726-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3726-2

Keywords

Search

Navigation